Sequential oncological therapy and delays in oncological diagnostics and treatment
Journal Title: OncoReview - Year 2014, Vol 4, Issue 2
Abstract
One of the causes behind the low recovery rate among oncological patients is late diagnosis and delayed treatment. To a large extent it stems from the limited access to standard diagnostic methods, and from the extended waiting time for medical treatment. Delayed diagnosis or commencement of therapy might be patient-related, doctor-related, or might have more to do with the organization of the healthcare system. It would appear that the greatest problem in Poland is the system-related delay. Studies have demonstrated that delayed treatment might have a significant impact on patient survival. Poor health education of the society, lack of comprehensive treatment, and queues for medical care that patients come across virtually at all treatment stages result in neoplastic diseases being diagnosed in their advanced stage only, with delayed treatment lowering the patients’ chances of complete recovery.
Authors and Affiliations
Karolina Skóra
Keywords
Related Articles
- EP ID EP67757
- DOI -
- Views 175
- Downloads 0
Efficacy and safety of liposomal doxorubicin in a patient treated for metastatic breast cancer
Liposomal doxorubicin is a newer form of chemotherapeutic agents that, due to its own special properties, preferably accumulates in cancer tissue. On the other hand, it shows lower affinity to cardiomyocytes and in this...
Hope
In our next article we would like to draw your attention to issue of hope. Taking into account our experience with one of our patient our goal is to establish what hope means for a person in the terminal phase of cancer....
Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib-sorafenib sequence
We presented a 39-year-old male who developed progressive cancer disease 4 years after nephrectomy due to clear cell carcinoma. He was diagnosed with locally reccurence and metastases to the liver, spleen and abdominal m...
Badanie kliniczne III fazy oceniające zastosowanie pazopanibu w leczeniu raka nerki – komentarz do badania
Leczenie nadpłytkowości samoistnej w ciąży - doświadczenia własne ośrodka
Nadpłytkowość samoistna (ET) jest przewlekłym nowotworem mieloproliferacyjnym dotyczącym głównie linii megakariocytów, przebiegającym ze zwiększoną ponad 450 000/ul liczbą płytek krwi. Nadpłytkowość występuje przede wszy...